A novel B-cell receptor – nuclear repressor ZEB2 axis that defines the clinical outcome in chronic lymphocytic leukaemia The growing understanding of protein markers on the surface of cancer cells helps to improve the success rate of blood cancer treatments. According to the Office for National Statistics, chronic lymphocytic leukaemia (CLL) is the most common malignant blood disease. Sadly, despite recent advances in drug development, CLL remains incurable and can transform into a highly aggressive form of cancer. There are newly-approved drugs designed to block the function of cancer cells. They do this by targeting the signalling functions of these proteins that reside on the surface of cancer cells. And while they have entered the clinic, and are revolutionising treatment, they are sadly prohibitively expensive in most cases. Dr Krysov’s research aims to unravel the control of the surface proteins and signalling inside CLL cells. If we better understand how these proteins and signalling functions work, we may be able to provide new targets for future drugs. Not only this, but we may be able to create treatments to work in tandem with the drugs already available and optimise their use. This research aims to investigate the effects of the factors that can directly influence the presence of surface proteins and the subsequent effects in malignant cells.